Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin in children and adolescents with irritability associated with autism spectrum disorder
NCT05555615Phase 3Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of pimavanserin in Autism Spectrum Disorder (ASD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent Adverse Events at 52 weeks. Started Nov 2022; status: terminated.
02
Drugs
pimavanserin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05555615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555615.